VEGFA and age-related macular degeneration: After dividing the study and control groups into subgroups according to their indications (AMD/PCV, RVO, DME, Myopic CNV), subgroup analysis demonstrated that the DME subgroup who received anti-VEGF therapy had a significantly higher incidence rate of becoming dialysis-dependent than their counterparts without receiving the same treatment—39.43 (95% CI: 32.90–47.27) for the anti-VEGF group and 17.45 (95% CI: 15.31–19.89) for the group without anti-VEGF.